Hallux Inc. is a leading pharmaceutical company based in Laguna Hills, CA, dedicated to addressing the widespread issue of onychomycosis, a fungal infection affecting 35 million Americans. With a focus on innovation, Hallux Inc. is currently investigating a new terbinafine topical product called Hallux Subungual Gel (HSG) as a potential solution for onychomycosis. This groundbreaking treatment approach involves periodic subungual applications by a physician, allowing new healthy nails to grow out clear of infection.
Recognizing the limitations of existing prescription antifungals, Hallux Inc. aims to provide a more effective and patient-friendly alternative. By conducting an open label study to evaluate HSG's efficacy, safety, tolerability, and pharmacokinetics in patients with distal lateral subungual onychomycosis (DLSO) of the toe, Hallux Inc. is committed to advancing the field of onychomycosis treatment and improving the lives of those affected by this condition.
Generated from the website